A tüdõrák immunterápiája

Translated title of the contribution: Immunotherapy for lung cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Similarly to other malignancies, immune checkpoint inhibitor therapy is a revolutionary, effective new treatment possibility for lung cancer. In lung cancer carcinogenesis is related mainly to tobacco smoking with high somatic mutation rate and immunogenicity. The PD-1 inhibitor nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab is a labelled indication in second line setting in advanced nonsmall cell lung cancer (NSCLC). Avelumab and durvalumab have promising activity as well. Based on the data of KEYNOTE 024 trial, pembrolizumab is approved in first line setting for cases with ≥50% PD-L1 expression. In this selected patient population, progression-free survival has doubled, and overall survival was significantly better in pembrolizumab-treated patients compared to those receiving standard of care. Pembrolizumab treatment became a new first line standard of care in advanced NSCLC. There are numerous ongoing clinical trials in lung cancer with immune checkpoint inhibitors in combination with cytotoxic chemotherapy, targeted agents, or in adjuvant setting.

Translated title of the contributionImmunotherapy for lung cancer
Original languageHungarian
Pages (from-to)153-157
Number of pages5
JournalMagyar onkologia
Volume61
Issue number2
Publication statusPublished - Jun 6 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Immunotherapy for lung cancer'. Together they form a unique fingerprint.

  • Cite this